KYOTO, Japan and PARAMUS, NJ: February 7, 2020 – Nippon Shinyaku Co., Ltd. (President, Shigenobu Maekawa) and NS Pharma, Inc. (President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku, announced today that the U.S. Food & Drug…Original Article
NDA Accepted for Filing by the FDA for Antisense Oligonucleotide Viltolarsen (NS-065/NCNP-01)
